Stay away from coadministration of pazopanib with robust CYP3A4 inhibitors if at all possible; if have to coadminister, reduce pazopanib dose to four hundred mg/dayMinor (1)dasatinib and pazopanib both enhance QTc interval. Small/Importance Unidentified.If coadministration of a QTc prolonging drug is unavoidable, keep an eye on for improved risk of